| DAY ONE / Wednesday, June 6 |
| 0800 |
Registration |
| 0845 |
Chairperson¡¯s Opening Remarks |
| 0900 |
Unveiling The Twelfth Five-Year Plan Guidelines & Impacts:What We Should Know for the National New Drug Innovation Plan? |
| 0930 |
Innovative Drugs in China and Progress in the Implementation of "National Major Special Projects on Drug Innovation¡± |
| 1030 |
Drug Innovation Showcase Sessions |
| In the following sessions, 20 Research institutes, Universities and Biotech companies will present their new drug innovations in those Categories: Novel Drug Candidates, New Targets, Innovative Drug Development Technology Platform |
| 1800 |
Close of Day One |
| DAY TWO / Thursday, June 7 |
| 0800 |
Registration |
| 0845 |
Chairperson¡¯s Opening Remarks |
| 0900 |
A Big Pharma¡¯s Perspective: Creating Value through Partnerships - Industry, Academy and Research |
| 0930 |
Partnering a Chinese Local Company with a Licensing and Co-Development Model: Providing FDA Standard Clinical Data in China for NDA in Both FDA and SFDA. |
| 1000 |
The Innovation Gap in Pharmaceutical Drug Discovery& New Models for R&D Success |
| 1030 |
Coffee Break |
| 1100 |
An Eternal Topic of R&D-Oriented Drug Companies: Patent Protection and Challenges Relating to Drug Discovery and Development in China |
| 1130 |
An Integrated Collaboration Model - Global Network of Phase I Centers for Oncology Trials Integrate the Service between SMO &CRO |
| 1200 |
Panel Discussion: Identifying the Right Partners in China and Negotiating for a Win-Win Partnership |
| 1245 |
Luncheon |
| 1400 |
Sponsor Presentation |
| 1430 |
Drug Screening Goes Digital? A Revolutionary Sample Preparation Tool from Tecan Streamlines Drug Discovery Process |
| 1500 |
An Introduction to High Content Screening and Analysis |
| 1530 |
Coffee Break |
| 1600 |
Drug Screening Technology: Quality and Diversity of Libraries of Small-Molecule Compounds |
| 1630 |
The Application of High Throughput Screening Technology In Identifying A New Class of Diuretics-¡±Urearetics¡± |
| 1700 |
Comprehensive Multi-omics High-throughput Solutions for Drug R&D |
| 1730 |
Translating Safety Biomarkers from the Lab to the Clinic |
| 1800 |
Close of Day Two |
| DAY THREE / Friday, June 8 |
| 0800 |
Registration |
| 0845 |
Chairperson¡¯s Opening Remarks |
| 0900 |
Concise overviews from regulatory experts to examine the latest updates and the regulatory scene in China |
| 0930 |
Pharma¡¯s Perspective: How to Navigate and Optimize Your regulatory Strategy in China |
| 1000 |
Preclinical Safety and ADME Evaluation in Drug Development |
| 1030 |
Coffee Break |
| 1100 |
Developing a Suitable Business Model for Your Preclinical Drug Development in China |
| 1130 |
Improving the Integration of PK/PD Modeling into the Drug Discovery and Development Process |
| 1200 |
Panel Discussion:An Industry Aspect-----China Clinical Trial Application and Consultation System |
| 1245 |
Luncheon |
| 1400 |
Designing and Conducting Successful Multi-regional Clinical Trials in Asia |
| 1430 |
Topic to be confirmed |
| 1500 |
Central Laboratory Meeting the Needs of China Clinical Trail |
| 1530 |
Coffee Break |
| 1600 |
Avoiding Common Mistakes and Pitfalls for Clinical trials supply Chain Regulatory Challenges in China |
| 1630 |
How to Initiate the First Global Trial for A Big Pharma in China |
| 1700 |
How to Build Early Stage Clinical Capabilities in China |
| 1730 |
Deploying Strategic Approaches to Address Critical Issues in Modern Clinical Trial Designs |
| 1800 |
Closing of Conference |
